This webinar roundtable explores interesting technologies, the scientific issues, the clinical opportunities for developing multivalent biologics platforms, whether certain technologies, such as antibodies, their fragments, or non-antibody scaffolds, are superior to others, the pros and cons of such bispecifics for improving management of patients, and licensing and commercial strategies.

A vast majority of businesses contract suppliers to provide goods and services to supplement their internal resources.

This all-purpose due diligence checklist contains a list of all the standard documents any buyer or partner might want to see.
.

The Life Sciences due diligence checklist covers unique characteristics applicable to your industry, which buyers or partners may want to examine.

Oncology venture funding, IPOs and partnerships have been exceptionally high in deal volume and values. Cancer continues to be the leading therapeutic area in the number and size of early deals, and the oncology pipeline continues to be a rich source of both follow-on agents as well as first-in-class programs.

In this whitepaper, learn what is artificial intelligence and how is it being applied to drug discovery, and much more.

This whitepaper provides a strategic perspective coupled with actionable tips to help guide you through the essential steps that will help maximize your chance of achieving success in biopharma partnering.

In this whitepaper, Linda Pullan provides licensing negotiations insights from a biotech business development perspective.

This white paper covers when to consider using suppliers, key differences between standard / OTS and custom part suppliers, tools and methods for managing suppliers, and when and how to transition between suppliers and internal resources.

This whitepaper provides actionable advice for Biotech business development leaders on how to get ready for a partnering deal.

This whitepaper evaluates the regulations that support GDP, best practices on how document contributors can apply the golden rule of research to their TMF, how to avoid writing too many and unnecessary Note-to-Files (NTFs), and tips on becoming inspection ready and staying that way.

This whitepaper discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value.